Newsfileยท2025-11-14 02:20Core Viewpoint - Rosen Law Firm is urging investors of Cytokinetics, Inc. to take action before the November 17, 2025 deadline related to a securities class action lawsuit concerning misleading statements about the company's New Drug Application for aficamten [2][6]. Group 1: Class Action Details - The class action pertains to investors who purchased Cytokinetics common stock between December 27, 2023, and May 6, 2025, and may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 17, 2025 [4][6]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - Rosen Law Firm has a history of significant settlements, including over $438 million secured for investors in 2019, and has been recognized for its success in securities class action settlements [5]. Group 3: Case Allegations - The lawsuit alleges that Cytokinetics made false and misleading statements regarding the timeline for the NDA submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [6]. - The company failed to disclose material risks related to the submission of a Risk Evaluation and Mitigation Strategy, which could delay the regulatory process, leading to investor damages when the true information was revealed [6].